Trade

with

PDL BioPharma Inc
(NASDAQ: PDLI)
AdChoices
8.33
+0.07
+0.85%
After Hours :
8.33
+0.00
+0.01%

Open

8.34

Previous Close

8.26

Volume (Avg)

3.17M (3.17M)

Day's Range

8.30-8.50

52Wk Range

7.22-10.26

Market Cap.

1.34B

Dividend Rate (Yield )

0.60 (7.20%)

Beta

0.60

Shares Outstanding

160.64M

P/E Ratio (EPS)

5.04 (1.65)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 442.92M

    • Net Income

    • 264.53M

    • Market Cap.

    • 1.34B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 56.64

    • PEG (Price/Earnings Growth) Ratio

    • 0.16

    • Beta

    • 0.60

    • Forward P/E

    • 2.87

    • Price/Sales

    • 2.86

    • Price/Book Value

    • 4.51

    • Price/Cash flow

    • 5.40

      • EBITDA

      • 431.98M

      • Return on Capital %

      • 42.84

      • Return on Equity %

      • 191.10

      • Return on Assets %

      • 42.84

      • Book Value/Share

      • 1.85

      • Shares Outstanding

      • 160.64M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.15 (12/3/2014)

      • Dividend Declaration Date

      • 1/30/2014

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 2.90

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -19.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 25.00

          • 17.04

          • Net Income

            Q/Q (last year)

          • -1.80

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 8.52

          • 63.43

          • Net Income

            5-Year Annual Average

          • 2.10

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 98.87

            • 82.75

            • Pre-Tax Margin

            • 89.35

            • 39.38

            • Net Profit Margin

            • 56.64

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 99.70

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 78.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 51.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.92

              • 0.76

              • Current Ratio

              • 0.75

              • 2.92

              • Quick Ratio

              • 0.73

              • 2.35

              • Interest Coverage

              • 14.41

              • 38.02

              • Leverage Ratio

              • 3.09

              • 2.21

              • Book Value/Share

              • 1.85

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 4.87

                • 243.90

                • P/E Ratio 5-Year High

                • 6.21

                • 634.30

                • P/E Ratio 5-Year Low

                • 2.82

                • 124.82

                • Price/Sales Ratio

                • 2.76

                • 9.29

                • Price/Book Value

                • 4.35

                • 8.39

                • Price/Cash Flow Ratio

                • 5.40

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 191.10

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 42.84

                    (61.80)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 54.22

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 28.23M

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.76

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  407.53M
                  Operating Margin
                  92.01
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  5.40
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  55.66%

                  Mutual Fund Ownership

                  49.90%

                  Float

                  87.88%

                  5% / Insider Ownership

                  2.49%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • First Trust NYSE Arca Biotech Fund

                  •  

                    6,357,447

                  • 2.03

                  • 4.41

                  • iShares Select Dividend

                  •  

                    5,928,927

                  • 0.08

                  • 4.08

                  • AEGON Intl Newton Real Ret

                  •  

                    5,779,778

                  • 0.00

                  • 3.61

                  • AEGON Intl Newton Global Higher Income

                  •  

                    4,734,720

                  • 0.00

                  • 2.95

                  • Vanguard Small Cap Index

                  •  

                    2,790,190

                  • -0.33

                  • 1.74

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,707,023

                  • 0.00

                  • 1.69

                  • iShares Russell 2000 (AU)

                  •  

                    2,418,115

                  • -1.81

                  • 1.66

                  • iShares Nasdaq Biotechnology

                  •  

                    2,088,101

                  • -0.24

                  • 1.44

                  • Schroder Glb Quant Act Val

                  •  

                    1,638,333

                  • 0.00

                  • 1.02

                  • Vanguard Small Cap Value Index Fund

                  •  

                    1,497,908

                  • 1.36

                  • 0.93

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Charger Corp.

                  •  

                    16,336,458

                  • +31.33%

                  • 10.17

                  • Renaissance Technologies Corp

                  •  

                    12,896,754

                  • +8.75%

                  • 8.05

                  • Newton Management Ltd

                  •  

                    12,343,629

                  • -2.24%

                  • 7.70

                  • BlackRock Fund Advisors

                  •  

                    11,384,180

                  • -1.11%

                  • 7.10

                  • Vanguard Group, Inc.

                  •  

                    10,169,706

                  • +2.13%

                  • 6.35

                  • Schroder Investment Management Ltd.

                  •  

                    8,092,140

                  • -0.63%

                  • 5.05

                  • Acadian Asset Management LLC

                  •  

                    6,593,444

                  • +1.64%

                  • 4.10

                  • Advisors Asset Management

                  •  

                    4,727,365

                  • +28.62%

                  • 2.95

                  • State Street Corp

                  •  

                    3,591,951

                  • -1.90%

                  • 2.24

                  • Wells Fargo Bank NA

                  •  

                    3,128,123

                  • +61.28%

                  • 1.95

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  High Yield

                  Style

                  Small Core

                  PDL BioPharma, Inc., was organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, the Company changed its name to PDL BioPharma, Inc. The Company is engaged in the discovery of a new generation of...more targeted treatments for cancer and immunologic diseases. The Company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents, covers among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in human...moreized antibodies and methods of producing humanized antibodies. It’s U.S. Patent; covers methods and materials used in the manufacture of humanized antibodies. The Company entered into licensing agreements under Queen et al. patents with entities that are independently developing or have developed humanized antibodies. The Company entered into patents license agreement with Genentech, Biogen Idec and Chugai; and it entered into a royalty purchase and sale agreement with Depomed, Inc. As on year ended December 31, 2013, the Company received Queen et al. patent royalties on sales of the eight humanized antibody products, all of which are currently approved for use by the FDA and other regulatory agencies outside the United States; including, Avastin®, Herceptin®, Xolair®, Lucentis®, Perjeta®, Kadcyla®, Tysabri® and Actemra®. The Company has also entered into licensing agreements under which it has licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials. The Company faces competition from other royalty buyers and enterprises. The Company’s licensees, borrowers and royalty-agreement counterparties are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities.lessless

                  Key People

                  Mr. John P. Mclaughlin

                  CEO/Director/President

                  Mr. Peter S. Garcia

                  CFO/Vice President

                  Christopher L. Stone

                  General Counsel/Secretary/Vice President

                  Mr. Danny Hart

                  Vice President, Divisional

                  Mr. David W. Gryska

                  Director

                  • PDL BioPharma Inc

                  • 932 Southwood Boulevard

                  • Incline Villiage, NV 89451

                  • USA.Map

                  • Phone: +1 775 832-8500

                  • Fax: +1 775 832-8501

                  • pdl.com

                  Incorporated

                  1986

                  Employees

                  10

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: